TGF-β Family Signaling in Development and Disease - Abstract The FASEB SRC TGF-β family in Development and Disease in 2026 (hereafter TGF-β 2026 ) will convene investigators who are advancing TGF-β research, from fundamental discovery through clinical application. This gathering unites researchers across the full spectrum of the TGF-β family, which encompasses over 30 ligands including TGF-βs, BMPs, GDFs, activins, and inhibins, who are driving innovations in cancer immunotherapy, regenerative medicine, vascular therapeutics, and age-related interventions. The conference program emphasizes mechanistic insights that inform therapeutic development, featuring sessions on cancer signaling mechanisms, development-disease intersections, vascular physiology and angiogenesis, tissue homeostasis, stem cell biology and regeneration, structure-function, and strategic therapeutic avenues. These presentations will showcase how advances in understanding TGF-β pathway regulation are being translated into clinical solutions for cancer, cardiovascular disease, immune disorders, musculoskeletal conditions, and aging-related pathologies. TGF-β 2026 represents the 14th iteration of this premier conference series, now spanning nearly 25 years of scientific evolution that has paralleled the field's maturation from basic signaling studies to therapeutic targeting. The sustained research momentum, with continued high publication and funding rates across TGF-β research domains, reflects the field's transition toward clinical impact and commercial development. This conference also bridges academic discovery with industry innovation, featuring speakers from leading pharmaceutical companies alongside academic researchers, creating opportunities for translational partnerships and therapeutic advancement discussions. The 2026 meeting will also foster cross- continental partnerships that have become essential for modern therapeutic development. Drawing from 13 previous conferences, TGF-β 2026 provides an intensive forum for sharing evaluating therapeutic targets, discussing regulatory pathways in model systems, and addressing translational challenges. The conference particularly emphasizes developing the next generation of TGF-β researchers equipped for the increasingly interdisciplinary and translational nature of the field, ensuring continued progress toward therapeutic breakthroughs that benefit human health.
